Cargando…
Progression in immunotherapy for advanced prostate cancer
Prostate cancer is one of the most common malignant cancers of the male genitourinary system and has high morbidity and mortality. Currently, treatment modalities for localized prostate cancer focus mainly on radical prostatectomy or radical radiation therapy. Some patients still experience disease...
Autores principales: | Liang, Hao, Liu, Yang, Guo, Jiao, Dou, Maoyang, Zhang, Xiaoyi, Hu, Liyong, Chen, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011447/ https://www.ncbi.nlm.nih.gov/pubmed/36925917 http://dx.doi.org/10.3389/fonc.2023.1126752 |
Ejemplares similares
-
CHMP4C as a novel marker regulates prostate cancer progression through cycle pathways and contributes to immunotherapy
por: Zhang, Hongtuan, et al.
Publicado: (2023) -
Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
por: Zhang, Xiaofei, et al.
Publicado: (2023) -
MRI radiomics predicts progression-free survival in prostate cancer
por: Jia, Yushan, et al.
Publicado: (2022) -
Photodynamic therapy for prostate cancer: Recent advances, challenges and opportunities
por: Xue, Qin, et al.
Publicado: (2022) -
Corrigendum: MRI radiomics predicts progression-free survival in prostate cancer
por: Jia, Yushan, et al.
Publicado: (2023)